中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
11期
69-70,107
,共3页
不稳定型心绞痛%超敏C反应蛋白%阿托伐他汀
不穩定型心絞痛%超敏C反應蛋白%阿託伐他汀
불은정형심교통%초민C반응단백%아탁벌타정
Unstable angina%Hs-CRP%Atorvastatin
目的:探讨早期大剂量应用阿托伐他汀治疗不稳定型心绞痛的临床疗效。方法选取2012年2月~2013年2月我院不稳定型心绞痛患者85例,按随机数字表法分为对照组(40例)和治疗组(45例)。两组均进行常规药物治疗,同时对照组给予阿托伐他汀10mg/d,治疗组给予阿托伐他汀20mg/d,并分别于治疗前后比较两组患者心血管事件发生率、血脂及超敏C反应蛋白(hs-CRP)水平。结果治疗7、15d后,治疗组hs-CRP水平均显著低于对照组,差异有统计学意义(P<0.05)。并且治疗后30d,治疗组LDL-C及TC达标率均优于对照组。结论早期较大剂量应用阿托伐他汀可以显著降低不稳定性心绞痛患者的hs-CRP及血脂水平,对于降低心血管事件发生率及改善患者预后具有重要意义。
目的:探討早期大劑量應用阿託伐他汀治療不穩定型心絞痛的臨床療效。方法選取2012年2月~2013年2月我院不穩定型心絞痛患者85例,按隨機數字錶法分為對照組(40例)和治療組(45例)。兩組均進行常規藥物治療,同時對照組給予阿託伐他汀10mg/d,治療組給予阿託伐他汀20mg/d,併分彆于治療前後比較兩組患者心血管事件髮生率、血脂及超敏C反應蛋白(hs-CRP)水平。結果治療7、15d後,治療組hs-CRP水平均顯著低于對照組,差異有統計學意義(P<0.05)。併且治療後30d,治療組LDL-C及TC達標率均優于對照組。結論早期較大劑量應用阿託伐他汀可以顯著降低不穩定性心絞痛患者的hs-CRP及血脂水平,對于降低心血管事件髮生率及改善患者預後具有重要意義。
목적:탐토조기대제량응용아탁벌타정치료불은정형심교통적림상료효。방법선취2012년2월~2013년2월아원불은정형심교통환자85례,안수궤수자표법분위대조조(40례)화치료조(45례)。량조균진행상규약물치료,동시대조조급여아탁벌타정10mg/d,치료조급여아탁벌타정20mg/d,병분별우치료전후비교량조환자심혈관사건발생솔、혈지급초민C반응단백(hs-CRP)수평。결과치료7、15d후,치료조hs-CRP수평균현저저우대조조,차이유통계학의의(P<0.05)。병차치료후30d,치료조LDL-C급TC체표솔균우우대조조。결론조기교대제량응용아탁벌타정가이현저강저불은정성심교통환자적hs-CRP급혈지수평,대우강저심혈관사건발생솔급개선환자예후구유중요의의。
Objective To explore the clinical efficacy of atorvastatin in large dose on unstable angina. Methods From February 2012 to February 2013, 85 cases of unstable angina of our hospital were randomly divided into two groups: The control group (40 cases) and treatment group (45 cases). Both group were treated with normal medicine, at the same time, the control group were given atorvastatin 10 mg/d, while the treatment group were given Atorvastatin 20mg/d. Compare the incidence of cardiovascular events, blood lipids and hs-CRP level before and after treatment. Results The hs-CRP level of the control group was significantly lower than the treatment group(P < 0.05) after 7days and 15days treatment. And the target rate of LDL-C and TC of the treatment group were all improved after 30days. Conclusion Early and large dose application of atorvastatin can significantly reduce the level of hs-CRP and blood lipid of patients with unstable angina, which contributes to the incidence of cardiovascular events and plays an improve role in improving patients' prognosis.